Literature DB >> 14015230

Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.

Z BRENER.   

Abstract

Entities:  

Keywords:  TRYPANOSOMIASIS, SOUTH AMERICAN

Mesh：

Year:  1962        PMID： 14015230

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN： 0036-4665            Impact factor:   1.846


× No keyword cloud information.
  188 in total

1.  Dominant T- and B-cell epitopes in an autoantigen linked to Chagas' disease.

Authors:  N Gironès; C I Rodríguez; E Carrasco-Marín; R F Hernáez; J L de Rego; M Fresno
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  Trypanosoma cruzi infection: do distinct populations cause intestinal motility alteration?

Authors:  Monica de Melo Medeiros; Tania C Araújo-Jorge; Wanderson S Batista; Tshaca Mahatma Oara Alves da Silva; Andréa Pereira de Souza
Journal:  Parasitol Res       Date:  2010-05-08       Impact factor: 2.289

3.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

4.  Modulation of thymocyte subsets during acute and chronic phases of experimental Trypanosoma cruzi infection.

Authors:  M C Leite-de-Moraes; M Hontebeyrie-Joskowicz; M Dardenne; W Savino
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

5.  In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.

Authors:  Rodrigo Hinojosa Valdez; Lilian Tatiani Düsman Tonin; Tânia Ueda-Nakamura; Sueli Oliveira Silva; Benedito Prado Dias Filho; Edilson Nobuyoshi Kaneshima; Sueli Fumie Yamada-Ogatta; Lucy Megumi Yamauchi; Maria Helena Sarragiotto; Celso Vataru Nakamura
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

6.  Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection.

Authors:  Valéria R A Pereira; Virginia M B Lorena; Mineo Nakazawa; Carlos F Luna; Edimilson D Silva; Antonio G P Ferreira; Marco Aurélio Krieger; Samuel Goldenberg; Milena B P Soares; Eridan M Coutinho; Rodrigo Correa-Oliveira; Yara M Gomes
Journal:  Parasitol Res       Date:  2005-04-27       Impact factor: 2.289

7.  Effect of recombinant tumour necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi.

Authors:  C M Black; D M Israelski; Y Suzuki; J S Remington
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

8.  Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles.

Authors:  Cristina Fonseca-Berzal; José Antonio Escario; Vicente J Arán; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2014-01-17       Impact factor: 2.289

9.  Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.

Authors:  Rômulo Dias Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Jerusa M Oliveira; Thaís V Carvalho; Mariana M Neves; Leandro L Oliveira; André Talvani
Journal:  Parasitol Res       Date:  2015-04-28       Impact factor: 2.289

10.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.